More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Wednesday's Economic News Crunch Could Tilt Markets
- NBA D-League On The Rise
- Japan Export Rebound Eases Fear of New Recession
- CNBC Anchor Takes a Sabbatical
- Citi Mortgage Reveals What Treasury Won't
- Rethinking Work
- Madoff—The Holiday Drink
- China Shipbuilding to Launch $937 Million China IPO
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Call Me Crazy: Confessions of a Black Friday Shopper
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- In Time for Holidays: More Gloom and Doom on Economy
- Market Pros Reveal Top Black Friday Trades
- Holiday Guide to This Season's Smartphones
- Turkey Day 101: How Well Do You Know Your Bird?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.
This morning the trio announced they're doing it today. An earlier-than-anticipated filing might mean the timeline for potential agency approval of the drug also gets moved up. Most seem to think a decision could come early next year. But as "Diabetic Investor" newsletter editor David Kliff told me, "God knows when with the FDA these days."
Separately, late yesterday AMLN announced it's laying off even more Byetta salespeople. And it tweaked the financial terms of its partnership with LLY. JPMorgan biotech analyst Cory Kasimov writes in a research note to clients, "This news should squelch any hopes for a near-term acquisition of AMLN by LLY." JPM has done and wants to do more investment banking for Amylin and it makes a market in the stock.
Kasimov also raises another interesting point about the Amylin restructuring announcement. "One could argue that this latest action was done under the (Icahn) gun...." Activist, billionaire investor Carl Icahn is in a heated proxy fight with AMLN. He wants shareholders to put his people on the Board of Directors and to then sell the company to Lilly. I, too, wonder whether these back-to-back announcements (especially the earlier-than-expected Byetta filing) out of Amylin are designed to show that management is trying to grab the bull by the horns and that it's got things under control ahead of the annual meeting on May 27th. Will it be enough to beat back Icahn?
Shares of LLY, AMLN and ALKS are all higher on the Byetta filing news and NovoNordisk is lower. NVO, the world's biggest diabetes drug company is waiting for FDA approval of a similar one-a-day drug, Victoza. But an FDA advisory panel recently raised concerns about a possible thyroid tumor risk that was seen in lab rodents on Victoza. And some analysts think the FDA will want to see if that is exclusive to NVO's drug or a so-called "class effect" that could also taint Byetta. In addition, the agency is still mulling over whether to put a pancreatitis warning on the Byetta label.
Most analysts think if or when once-a-week Byetta gets to market that it will become a multi-billion dollar blockbuster, although some have been lowering their sales estimates lately. The drug's fate could be determined by what the FDA decides to do about the small, possibly even unrelated risk of pancreatitis. Will it issue a warning? And if it does, how severe will it be?
In the meantime, Lilly, Amylin and Alkermes investors are pouring a few margaritas. Salud!
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes